Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TRINITY BIOTECH PLC Regulatory Filings 2020

Jul 13, 2020

35392_rns_2020-07-13_072028c2-9c92-4b43-b296-a942c86de007.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

CORRESP 1 filename1.htm Licensed to: ZKG Document created using EDGARfilings PROfile 7.0.1.0 Copyright 1995 - 2020 Broadridge

[LETTERHEAD OF TRINITY BIOTECH Plc]

July 13, 2020

VIA EDGAR

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attn: Charles Edwards, Esq.

Re: Trinity Biotech Plc Registration Statement on Form F-3 File No. 333-239701

Dear Mr. Edwards:

The undersigned, on behalf of Trinity Biotech Plc (“Trinity”), issuer of the securities covered by the above-referenced Registration Statement, hereby respectfully requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission at 4:00 p.m. Washington, D.C. time on Wednesday, July 15, 2020, or as soon thereafter as possible.

Management of Trinity is aware of its responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the disposition of the securities covered by the above-referenced Registration Statement.

Thank you very much for your courtesy in this matter.

Very truly yours,
/s/ Kevin Tansley
Kevin Tansley
Chief Financial Officer